Literature DB >> 16332731

OXA (beta)-lactamases in Acinetobacter: the story so far.

Susan Brown1, Sebastian Amyes.   

Abstract

The emergence of carbapenem resistance in Acinetobacter baumannii has become a global concern since these beta-lactams are often the only effective treatment left against many multiresistant strains. A recent development has been the discovery of a novel group of narrow-spectrum OXA beta-lactamases in carbapenem-resistant strains, some of which have acquired the ability to hydrolyse the carbapenems. The first of these was found in a strain isolated in Edinburgh before imipenem was in use in the hospital. Whether these carbapenemases have been acquired or are part of the genetic make-up of this species has yet to be determined. More importantly, however, they represent an important stage in the evolution of antibiotic resistance in Acinetobacter. This paper discusses the emergence of these unusual enzymes over the past decade.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16332731     DOI: 10.1093/jac/dki425

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  58 in total

1.  Investigation of the molecular epidemiology of Acinetobacter baumannii isolated from patients and environmental contamination.

Authors:  Chunmei Ying; Yongli Li; Yaping Wang; Bing Zheng; Chengde Yang
Journal:  J Antibiot (Tokyo)       Date:  2015-04-15       Impact factor: 2.649

2.  In-silico modeling of a novel OXA-51 from β-lactam-resistant Acinetobacter baumannii and its interaction with various antibiotics.

Authors:  Vishvanath Tiwari; Isha Nagpal; Naidu Subbarao; Rajeswari R Moganty
Journal:  J Mol Model       Date:  2012-01-22       Impact factor: 1.810

3.  Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40.

Authors:  Karen Lolans; Thomas W Rice; L Silvia Munoz-Price; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

4.  Dissemination of Acinetobacter baumannii clones with OXA-23 Carbapenemase in Colombian hospitals.

Authors:  Maria Virginia Villegas; Juan Nicolas Kattan; Adriana Correa; Karen Lolans; Ana Maria Guzman; Neil Woodford; David Livermore; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

Review 5.  Carbapenemases: the versatile beta-lactamases.

Authors:  Anne Marie Queenan; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

Review 6.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

7.  Characterization of genetic diversity of carbapenem-resistant Acinetobacter baumannii clinical strains collected from 2004 to 2007.

Authors:  Chao Qi; Michael Malczynski; Michelle Parker; Marc H Scheetz
Journal:  J Clin Microbiol       Date:  2008-01-23       Impact factor: 5.948

8.  Four Year Trend of Carbapenem-Resistance in Newly Opened ICUs of a University-Affiliated Hospital of South Korea.

Authors:  Bo Min Kim; Eun Ju Jeon; Ju Young Jang; Jin-Won Chung; Jihoon Park; Jae Chol Choi; Jong Wook Shin; In Won Park; Byoung Whui Choi; Jae Yeol Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-04-30

9.  OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.

Authors:  Paul G Higgins; Laurent Poirel; Marlene Lehmann; Patrice Nordmann; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

10.  Penicillin sulfone inhibitors of class D beta-lactamases.

Authors:  Sarah M Drawz; Christopher R Bethel; Venkata R Doppalapudi; Anjaneyulu Sheri; Sundar Ram Reddy Pagadala; Andrea M Hujer; Marion J Skalweit; Vernon E Anderson; Shu G Chen; John D Buynak; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.